Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Vamikibart (RO7200220) in Uveitic Macular Edema
jRCT2051220203Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of vamikibart in uveitic macular edema (UME) and noninfectious uveitis (NIU) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Proportion of participants with ≥15-letter improvement in BCVA at Week 16. Started Jun 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)noninfectious uveitis (NIU)
Beyond the preview
Go deeper on jRCT2051220203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220203.